{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:38:09Z","timestamp":1779230289014,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12933-017-0611-x","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T07:42:46Z","timestamp":1507794166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?"],"prefix":"10.1186","volume":"16","author":[{"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-0939","authenticated-orcid":false,"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"issue":"22","key":"611_CR1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl J Med. 2015;373(22):2117\u201328.","journal-title":"New Engl J Med"},{"issue":"10","key":"611_CR2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"issue":"7","key":"611_CR3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New Engl J Med. 2017;377(7):644\u201357.","journal-title":"New Engl J Med"},{"issue":"4","key":"611_CR4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","volume":"15","author":"K Stenlof","year":"2013","unstructured":"Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372\u201382.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"611_CR5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","volume":"16","author":"T Forst","year":"2014","unstructured":"Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P. Efficacy and safety of canagliflozin over 52\u00a0weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467\u201377.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"611_CR6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc14-1237","volume":"38","author":"B Neal","year":"2015","unstructured":"Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403\u201311.","journal-title":"Diabetes Care"},{"key":"611_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CE.S109654","volume":"12","author":"T Karagiannis","year":"2017","unstructured":"Karagiannis T, Bekiari E, Tsapas A. Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evid. 2017;12:1\u201310.","journal-title":"Core Evid"},{"key":"611_CR8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12933-016-0407-4","volume":"15","author":"N Inagaki","year":"2016","unstructured":"Inagaki N, Harashima S, Maruyama N, Kawaguchi Y, Goda M, Iijima H. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016;15:89.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"611_CR9","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","volume":"70","author":"JL Januzzi Jr","year":"2017","unstructured":"Januzzi JL Jr, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies MJ. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70(6):704\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"611_CR10","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","volume":"5","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Avogaro A. SGTL2 inhibitors and amputations in the US FDA adverse event reporting system. Lancet Diabetes Endocrinol. 2017;5(9):680\u20131.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"611_CR11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/dc11-1360","volume":"35","author":"Y Li","year":"2012","unstructured":"Li Y, Burrows NR, Gregg EW, Albright A, Geiss LS. Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40\u00a0years or older: US, 1988\u20132008. Diabetes Care. 2012;35(2):273\u20137.","journal-title":"Diabetes Care"},{"key":"611_CR12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12933-015-0315-z","volume":"14","author":"M Baba","year":"2015","unstructured":"Baba M, Davis WA, Norman PE, Davis TM. Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the fremantle diabetes study. Cardiovasc Diabetol. 2015;14:152.","journal-title":"Cardiovasc Diabetol"},{"key":"611_CR13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.diabres.2017.07.029","volume":"132","author":"WD Rinkel","year":"2017","unstructured":"Rinkel WD, Luiten J, van Dongen J, Kuppens B, Van Neck JW, Polinder S, Castro Cabezas M, Coert JH. In-hospital costs of diabetic foot disease treated by a multidisciplinary foot team. Diabetes Res Clin Pract. 2017;132:68\u201378.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"611_CR14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ejvs.2013.07.010","volume":"46","author":"K Winell","year":"2013","unstructured":"Winell K, Venermo M, Ikonen T, Sund R. Indicators for comparing the incidence of diabetic amputations: a nationwide population-based register study. Eur J Vasc Endovasc Surg. 2013;46(5):569\u201374.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"2","key":"611_CR15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2337\/dc08-1639","volume":"32","author":"A Johannesson","year":"2009","unstructured":"Johannesson A, Larsson GU, Ramstrand N, Turkiewicz A, Wirehn AB, Atroshi I. Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations. Diabetes Care. 2009;32(2):275\u201380.","journal-title":"Diabetes Care"},{"issue":"1","key":"611_CR16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-016-0446-x","volume":"15","author":"K Mohammedi","year":"2016","unstructured":"Mohammedi K, Woodward M, Hirakawa Y, Zoungas S, Colagiuri S, Hamet P, Harrap S, Poulter N, Matthews DR, Marre M, et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovasc Diabetol. 2016;15(1):129.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"611_CR17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejvs.2017.07.005","volume":"54","author":"E Baubeta Fridh","year":"2017","unstructured":"Baubeta Fridh E, Andersson M, Thuresson M, Sigvant B, Kragsterman B, Johansson S, Hasvold P, Falkenberg M, Nordanstig J. Amputation rates, mortality, and pre-operative comorbidities in patients revascularised for intermittent claudication or critical limb ischaemia: a population based study. European J Vasc Endovasc Surg. 2017;54(4):480\u20136.","journal-title":"European J Vasc Endovasc Surg"},{"issue":"7","key":"611_CR18","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","volume":"34","author":"S Kohler","year":"2017","unstructured":"Kohler S, Zeller C, Iliev H, Kaspers S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I\u2013III clinical trials. Adv Ther. 2017;34(7):1707\u201326.","journal-title":"Adv Ther"},{"key":"611_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13115","author":"Z Yuan","year":"2017","unstructured":"Yuan Z, DeFalco FJ, Ryan PB, Schuemie MJ, Stang PE, Berlin JA, Desai M, Rosenthal N. Risk of lower extremity amputations in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors in the United States: a retrospective cohort study. Diabetes Obes Metab. 2017. doi:\n                        10.1111\/dom.13115\n                        \n                    .","journal-title":"Diabetes Obes Metab"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-017-0611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T07:42:53Z","timestamp":1507794173000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-017-0611-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1186\/s12933-017-0611-x","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]},"article-number":"129"}}